BOLD Earnings Date: Nov 5, 2026 (Estimated) — Boundless Bio, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is BOLD's next earnings date?
Boundless Bio, Inc. (BOLD) is expected to report earnings on Thursday, November 5, 2026; the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.56.
How did BOLD do in its last earnings report?
In its most recent report on Aug 7, 2026 (Q2 2026), Boundless Bio, Inc. posted EPS of -$1.06 versus the -$0.57 estimate, a miss of 86.0%. Revenue was $0. The stock's 1-day post-earnings move was +1.8%.
How much does BOLD stock move after earnings?
BOLD beat EPS estimates in 2 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 3.5% (up or down) in the day after earnings.
About Boundless Bio, Inc.
Boundless Bio, Inc., a clinical-stage oncology company, focuses on developing innovative cancer therapies aimed at addressing the significant unmet needs of patients with oncogene amplified tumors. Their core strategy involves targeting extrachromosomal DNA (ecDNA). The company's lead product candidate, BBI-355, an orally administered inhibitor of checkpoint kinase 1 (CHK1), is currently in Phase 1/2 clinical trials for patients suffering from oncogene amplified cancers. Additionally, Boundless Bio is advancing BBI-825, another oral inhibitor, this one targeting ribonucleotide reductase (RNR), also in Phase 1/2 clinical development for cancer patients exhibiting resistance gene amplifications. A third initiative, the ecDTx 3 program, is designed to target a kinesin crucial for the cellular segregation mechanism of ecDNA. Incorporated in 2018, the company originally operated as Pretzel Therapeutics, Inc. before adopting the name Boundless Bio, Inc. in July 2019. Its headquarters are situated in San Diego, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 | Q2 2026 | -0.57 | -1.06 | -85.96% | $0 | ❌ Miss | +1.76% | -2.29% | +1.06% |
| 2026-08-04 | -1.06 | -1.06 | +0.00% | — | ➖ Inline | +8.95% | +9.73% | +12.45% | |
| 2026-05-08 | Q1 2026 | -0.55 | -0.60 | -9.09% | $0 | ❌ Miss | -5.88% | +1.31% | -6.54% |
| 2026-03-09 | Q4 2025 | -0.49 | -0.58 | -18.37% | $0 | ❌ Miss | +0.89% | -1.77% | +0.89% |
| 2025-11-05 | Q3 2025 | -0.56 | -0.62 | -10.71% | $0 | ❌ Miss | -3.08% | -3.08% | -15.38% |
| 2025-08-05 | Q2 2025 | -0.69 | -0.70 | -1.45% | $0 | ❌ Miss | -1.67% | -7.50% | -4.17% |
| 2025-03-27 | Q4 2024 | -0.78 | -0.74 | +5.13% | $0 | ✅ Beat | -0.66% | -1.97% | -3.29% |
| 2024-11-07 | Q3 2024 | -0.75 | -0.74 | +1.33% | $0 | ✅ Beat | +5.42% | -2.41% | -14.16% |
Showing last 8 quarters.